Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Nabriva Therapeutics Plc (NBRV) EUR0.01

Sell:$1.75 Buy:$1.76 Change: $0.03 (1.69%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$1.75
Buy:$1.76
Change: $0.03 (1.69%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$1.75
Buy:$1.76
Change: $0.03 (1.69%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Contact details

Address:
56 Fitzwilliam Square North
DUBLIN
2
Ireland
Telephone:
+ ()
Website:
https://www.nabriva.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NBRV
ISIN:
IE00BYQMW233
Market cap:
$138.68 million
Shares in issue:
78.35 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Ireland
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Daniel Burgess
    Independent Chairman of the Supervisory Board
  • Steven Gelone
    President, Chief Operating Officer
  • Theodore Schroeder
    Chief Executive Officer, Director
  • Gary Sender
    Chief Financial Officer
  • Robert Crotty
    General Counsel, Secretary
  • Francesco Lavino
    Chief Commercial Officer
  • Jennifer Schranz
    chief medical officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.